CMS advises Sirion Biotech shareholders on acquisition by PerkinElmer

Munich – Listed US company PerkinElmer, Inc. has acquired SIRION BIOTECH, a leading global provider of viral vector-based technologies for cell and gene therapies. Sirion has established a strong portfolio of licensed vector technologies leveraged by over a dozen major pharmaceutical and biotech players researching more than 25 diseases and conditions. As part of the transaction, shareholders including High-Tech Gründerfonds (HTGF), Creathor Venture, KfW and Bayern Kapital sold their stakes in the firm, which is based in Martinsried near Munich. The shareholders had held an equity interest in SIRION since 2007 resulting from several venture capital rounds of financing.

A CMS team headed by lead partners Stefan-Ulrich Müller and Dr Michael Wangemann advised and represented the shareholders in SIRION BIOTECH on all legal aspects of selling all their shares. The Munich-based CMS venture capital team regularly advises life science companies and their shareholders, particularly on financing rounds, including venture debt transactions, and on exits.

CMS Germany

Stefan-Ulrich Müller, Lead Partner, Munich
Dr Michael Wangemann, Lead Partner, Munich
Dr Tilman Weichert, Partner, Munich
Viktoria Barthel, Associate, Munich
Sebastian Hummel, Associate, Munich, all Corporate/M&A, Venture Capital
Jörg Schrade, Partner, Munich, Tax
Stefan Lüft, Partner, Munich
Annika Lindemann, Senior Associate, Munich, both Intellectual Property
Dr Benedikt Forschner, Counsel, Munich, Labor, Employment & Pensions
Dr Markus Kaulartz, Counsel, Munich, TMC
Stefan Lehr, Partner, Frankfurt/Main, Competition & EU
Barbara Bayer, Counsel, Frankfurt/Main, Banking & Finance

Press Contact
[email protected]